BeiGene
ONC
$410.67
Share price
-4.40%
Change (1 day)
58.82%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (ONC) - Net assets
Net assets on the balance sheet as of December 2024 : NZ$5.58 Billion
According to BeiGene
's latest financial reports the company has NZ$5.58 Billion in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
BeiGene - Net assets on balance sheet (from 2014 to 2024)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2024-12-31 | $NZ$5.90 B | 5.63% |
| 2023-12-31 | $NZ$5.59 B | -18.98% |
| 2022-12-31 | $NZ$6.90 B | -23.1% |
| 2021-12-31 | $NZ$8.97 B | 67.43% |
| 2020-12-31 | $NZ$5.36 B | 269.14% |
| 2019-12-31 | $NZ$1.45 B | -44.43% |
| 2018-12-31 | $NZ$2.61 B | 171.36% |
| 2017-12-31 | $NZ$0.96 B | 89.1% |
| 2016-12-31 | $NZ$0.50 B | 369.18% |
| 2015-12-31 | $NZ$0.10 B | 230.18% |
| 2014-12-31 | $NZ$32.88 M | -169.79% |
| 2013-12-31 | $-NZ$47.13 Million |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 | NZ$10.08 M | -99.82% | 🇺🇸 USA |
 | NZ$2.28 B | -59.02% | 🇺🇸 USA |